Literature DB >> 14562104

RNA molecules stimulate prion protein conversion.

Nathan R Deleault1, Ralf W Lucassen, Surachai Supattapone.   

Abstract

Much evidence supports the hypothesis that the infectious agents of prion diseases are devoid of nucleic acid, and instead are composed of a specific infectious protein. This protein, PrP(Sc), seems to be generated by template-induced conformational change of a normally expressed glycoprotein, PrP(C) (ref. 2). Although numerous studies have established the conversion of PrP(C) to PrP(Sc) as the central pathogenic event of prion disease, it is unknown whether cellular factors other than PrP(C) might be required to stimulate efficient PrP(Sc) production. We investigated the biochemical amplification of protease-resistant PrP(Sc)-like protein (PrPres) using a modified version of the protein-misfolding cyclic amplification method. Here we report that stoichiometric transformation of PrP(C) to PrPres in vitro requires specific RNA molecules. Notably, whereas mammalian RNA preparations stimulate in vitro amplification of PrPres, RNA preparations from invertebrate species do not. Our findings suggest that host-encoded stimulatory RNA molecules may have a role in the pathogenesis of prion disease. They also provide a practical approach to improve the sensitivity of diagnostic techniques based on PrPres amplification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14562104     DOI: 10.1038/nature01979

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  188 in total

1.  Functional mechanisms of the cellular prion protein (PrP(C)) associated anti-HIV-1 properties.

Authors:  Sandrine Alais; Ricardo Soto-Rifo; Vincent Balter; Henri Gruffat; Evelyne Manet; Laurent Schaeffer; Jean Luc Darlix; Andrea Cimarelli; Graça Raposo; Théophile Ohlmann; Pascal Leblanc
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

2.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation.

Authors:  Erwann Rousseau; Benjamin Dehay; Léa Ben-Haïem; Yvon Trottier; Michel Morange; Anne Bertolotti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

3.  Autocatalytic self-propagation of misfolded prion protein.

Authors:  Jan Bieschke; Petra Weber; Nikolaus Sarafoff; Michael Beekes; Armin Giese; Hans Kretzschmar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

4.  Concern about mad cow disease: end of the beginning, or beginning of the end?

Authors:  Herbert Budka
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

5.  Case for an RNA-prion world: a hypothesis based on conformational diversity.

Authors:  Param Priya Singh; Anirban Banerji
Journal:  J Biol Phys       Date:  2011-02-08       Impact factor: 1.365

Review 6.  Prions on the move.

Authors:  Charles Weissmann; Jiali Li; Sukhvir P Mahal; Shawn Browning
Journal:  EMBO Rep       Date:  2011-10-28       Impact factor: 8.807

Review 7.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

8.  A viral suppressor protein inhibits host RNA silencing by hooking up with Argonautes.

Authors:  Hailing Jin; Jian-Kang Zhu
Journal:  Genes Dev       Date:  2010-05       Impact factor: 11.361

9.  Generation of prions in vitro and the protein-only hypothesis.

Authors:  Rodrigo Diaz-Espinoza; Claudio Soto
Journal:  Prion       Date:  2010-04-05       Impact factor: 3.931

10.  Testing the possibility to protect bovine PrPC transgenic Swiss mice against bovine PrPSc infection by DNA vaccination using recombinant plasmid vectors harboring and expressing the complete or partial cDNA sequences of bovine PrPC.

Authors:  Sandra Müller; Roland Kehm; Michaela Handermann; Nurith J Jakob; Udo Bahr; Björn Schröder; Gholamreza Darai
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.